KIN-8194 is a novel dual inhibitor of HCK and BTK that has shown the potent and selective in vitro killing of MYD88-mutated lymphoma cells, including ibrutinib-resistant BTKC481S-expressing cells, and demonstrated excellent bioavailability, pharmacokinetic parameters, and good tolerance at active doses [113]. Here, BTK is linked to lymphoma.